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Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease of the motor nervous system. We
show using multielectrode array and patch-clamp
recordings that hyperexcitability detected by clinical
neurophysiological studies of ALSpatients is recapit-
ulated in induced pluripotent stemcell-derivedmotor
neurons from ALS patients harboring superoxide
dismutase 1 (SOD1), C9orf72, and fused-in-sarcoma
mutations. Motor neurons produced from a geneti-
cally corrected but otherwise isogenic SOD1+/+
stem cell line do not display the hyperexcitability
phenotype. SOD1A4V/+ ALS patient-derived motor
neurons have reduced delayed-rectifier potassium
current amplitudes relative to control-derived motor
neurons, a deficit that may underlie their hyperexcit-
ability. The Kv7 channel activator retigabine both
blocks the hyperexcitability and improves motor
neuron survival in vitro when tested in SOD1 mutant
ALS cases. Therefore, electrophysiological charac-
terization of human stem cell-derived neurons can
reveal disease-related mechanisms and identify
therapeutic candidates.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating, untreatable
disease of upper and lower motor neurons (Kiernan et al., 2011).
The excitotoxicity neurodegeneration hypothesis posits that
excessive glutamatergic synaptic activity in ALS leads to cal-
cium overload and cell death (Cleveland and Rothstein, 2001;
Pasinelli and Brown, 2006). However, nerve conduction studiesevaluating axonal threshold (strength-duration time constant
and recovery cycle times) in ALS patients demonstrate
increased axonal membrane excitability, well away from any
synapses (Bostock et al., 1995; Kanai et al., 2006; Nakata
et al., 2006; Vucic and Kiernan, 2006), and the degree of hyper-
excitability correlates with patient survival (Kanai et al., 2012).
Increased membrane excitability may be important then as
a contributor to disease, and modeling suggests that either
increased persistent sodium or reduced delayed-rectifier potas-
sium currents could be responsible for the axonal hyperexcitabil-
ity (Kanai et al., 2006; Tamura et al., 2006). However, whether
excitability results from autonomous changes in motor neurons
cannot be determined by this technique (Fritz et al., 2013).
About 10% of ALS cases are familial, and, of these, superox-
ide dismutase 1 (SOD1) mutations account for about 20%.Motor
neurons from SOD1G93A mice, which overexpress this human
mutant SOD1 protein, also show hyperexcitability (Kuo et al.,
2004; Pieri et al., 2003; van Zundert et al., 2008), at least in
part due to increased persistent sodium currents. Because of
the distinct clinical and pathological features of SOD1 ALS
compared to other variants (Ince et al., 2011), it is unclear if pri-
marymotor neuron hyperexcitability represents a general feature
of ALS or a specific characteristic of SOD1-mediated disease.
Hyperexcitability in motor neurons of other familial ALS etiol-
ogies, such as C9orf72 hexanucleotide repeat expansions and
fused-in-sarcoma (FUS) mutations, have not yet been similarly
evaluated because of a lack of mouse models.
Induced pluripotent stem cell (iPSC) technology enables neu-
rons of specificdisease-relevant subtypes to bederived fromdis-
ease patients and control subjects and thereby provides an
in vitro platform for discovering human neuron phenotypes that
may reflect the individual diseases. However, the number of sub-
ject cell lines employed in studies utilizing this technique has so
far beensmall (SandoeandEggan, 2013). Thus, it is currently diffi-
cult to know how consistent such findings are across largeCell Reports 7, 1–11, April 10, 2014 ª2014 The Authors 1
numbers of patients, and if the results represent disease-specific
phenotypes or differences among cell lines. We address these
issues here in twoways. First, we use a gene-targeted correction
of the disease-causing SOD1 mutation to produce otherwise
isogenic stem cells bearing wild-type SOD1 alleles (Kiskinis
et al., 2014) and show that the gene correction abrogates the
phenotype of ALS motor neuron hyperexcitability. Second, we
demonstrate that hyperexcitability is present among motor neu-
ronsderived fromeightALSpatients of three separate genetic eti-
ologies compared to five control patients, together constituting
the largest sample group to date for these types of studies.
ALS-derived motor neurons have reduced delayed-rectifier
voltage-gatedpotassiumcurrents compared tocontrols. Further-
more, retigabine, an activator ofKv7potassiumchannels reduces
excitability to levels seen in controls. Retigabine increases
the in vitro survival of SOD1A4V/+ ALS motor neurons, support-
ing the hypotheses that motor neuron hyperexcitability may
contribute to motor neuron degeneration in ALS. The hyperexcit-
ability phenotype and blockade of firing by retigabine are present
across a wide range of familial ALS patients harboring additional
SOD1 mutations, C9orf72 repeat expansions, and FUS muta-
tions. An iPSC-based disease-modeling approach can validate
a clinically relevant phenotype in human motor neurons, reveal
mechanisms underlying the phenotype, and help evaluate ac-
tions of candidate drugs on the disease-specific phenotype.
RESULTS
Hyperexcitability of SOD1A4V-Derived Motor Neurons
Using Multielectrode Array Recording
We performed an initial set of electrophysiological phenotyping
experiments using iPSC-derivedmotor neurons from two control
subjects (11a, 18a) and two unrelated familial ALS patients (39b
and RB9d) harboring the same aggressive SOD1A4V/+ mutation.
All iPSC lines were generated via three-factor (OCT4, SOX2,
KLF4) retroviral reprogramming, had a normal karyotype, and
differentiated into motor neurons after robust neuralization
based on dual SMAD inhibition (Chambers et al., 2009) and
specification through exposure to retinoic acid and induction
of sonic hedgehog signaling (Boulting et al., 2011; Kiskinis
et al., 2014; Figure 1A).
We recorded spontaneous firing of iPSC-derived motor neu-
rons using extracellular multielectrode arrays (MEAs), whereby
the action potentials of individual neurons are detected by a
grid of 64 extracellular electrodes embedded in each culture
well. In four separate experiments, control and SOD1 ALS
iPSC lines were cultured synchronously, differentiated into mo-
tor neurons in parallel, and plated in equal numbers on MEAs,
which allowed recording of the spontaneous firing (Hanson and
Landmesser, 2004) in hundreds of control and ALS patient-
derived neurons per differentiation after culturing for 4 weeks.
We observed significantly more spontaneous action potentials
in SOD1A4V/+ relative to control cultures (p < 0.05, t test; Figures
1B and 1C). Action potentials were sorted by spike morphology
and timing to derive clusters corresponding to individual neurons
(Figure S1) (Cohen and Kohn, 2011), and a significantly higher
averagemean firing rate was observed in the SOD1A4V/+ neurons
(p < 1015, t test; Figures 1D and 1E).2 Cell Reports 7, 1–11, April 10, 2014 ª2014 The AuthorsWeperformed two experiments to confirm that the hyperexcit-
ability on the MEAs resulted from motor neurons. First, to test if
the difference in spontaneous action potential firing resulted
from a larger number or more active population of inhibitory neu-
rons in control cultures, we applied GABAergic and glycinergic
transmission blockers. The blockers did not increase action po-
tential firing rates (p = 0.61, t test, for bicuculline; p = 0.24, t test,
for strychnine; Figure S2), suggesting that activity of inhibitory
neurons wasminimal and that the heightened spontaneous firing
in the MEA recordings of ALS-derived motor neurons reflected
an intrinsic increase in excitability.
Second, we inserted a Hb9::GFP reporter into the AAVS1
locus for iPSCs 18a and 39b (Figure S3A), allowing fluores-
cence-activated cell sorting (FACS) purification of GFP-positive
motor neurons for recording on the arrays (Figures S3B and
S3C). We recorded every 4 days and observed that 39b
Hb9::GFP motor neurons consistently fired more action poten-
tials than 18a Hb9::GFP motor neurons over the entire time
course (mixed model ANOVA F-test p = 1 3 104 for difference
between lines; post hoc t tests after Bonferroni correction for
multiple comparisons for day 12, p = 0.0055; day 16, p =
0.0030; day 20, p = 0.0057; day 24, p = 0.0029; day 28, p =
0.015; Figure 1F). Thus, the hyperexcitability must be due to
motor neurons, because only Hb9-positive motor neurons
were plated on the arrays.
Correction of the SOD1A4V Mutation Eliminates the
Hyperexcitability Phenotype
To test if increased action potential firing was a direct effect of
the SOD1A4V mutation, we took advantage of a gene-targeted
derivative of the 39b iPSC line in which the A4V-encoding muta-
tion had been corrected to a wild-type sequence by homologous
recombination, 39b-SOD1+/+ (abbreviated 39b-Cor; Kiskinis
et al., 2014). Because substantial motor neuron death begins
in ALS motor neurons after 15 days of neuronal maturation in
our culture conditions (Kiskinis et al., 2014) and because the hy-
perexcitability phenotype in the ALS motor neurons was detect-
able at this early time point (Figure 1F), we compared MEA
recordings of 39b and isogenic-derived 39b-Cor motor neurons
at 14 days, to avoid the possibility that increased firing reflected
either neuronal death or select survival of hyperexcitable neu-
rons (Table S1). Although the baseline spike rate was lower at
14 than 28 days, patient-derived 39b neurons had a higher spon-
taneous firing rate than neurons in which the SOD1mutation was
corrected (p = 0.01 for total rate, t test; Figure 1G; average mean
firing rate 1.30 ± 0.10 Hz for n = 122 39b-Cor and 1.50 ± 0.08 Hz
for n = 208 39b; p < 0.05, t test). We conclude that the hyperex-
citability phenotype reflects the presence of the disease-initi-
ating mutation and precedes progressive motor neuron death.
Confirmation of ALSMotor NeuronHyperexcitability and
Mechanistic Exploration Using Whole-Cell Patch Clamp
To examine the electrophysiological properties of identified indi-
vidual motor neurons, we transduced developing neurons with
anHb9::RFP lentiviral reporter and recorded only fromRFP-pos-
itive motor neurons (Marchetto et al., 2008) using whole-cell
patch clamp (Figure 2A). Both control- and SOD1 ALS-derived
motor neurons were electrically excitable. To quantify the degree
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Figure 1. Multielectrode Array Recording Reveals Increased Spontaneous Firing in ALS-Derived Neurons Compared to Control-Derived
Neurons
(A) Schematic of differentiation and recording.
(B) Representative recordings from four out of 64 MEA electrodes in control (11a, 18a) and ALS (39b, RB9d)-derived neurons cultured for 28 days on the arrays.
(C) Total action potential firing rate during 1 min of recording from MEAs (11a, n = 3; 18a, n = 3; control mean 6,510 ± 3,131 spikes/min; 39b, n = 3; RB9d, n = 3;
ALS mean 20,528 ± 5,069 spikes/min; p < 0.05, t test).
(D) Mean firing rate histograms of individual neurons from MEAs in (B). See also Figure S1.
(E) Average of mean firing rate for patient-derived neurons (11a, n = 381; 18a, n = 191; control mean 1.17 ± 0.04 Hz; 39b, n = 520; RB9d, n = 662; ALSmean 1.76 ±
0.05 Hz; p < 1015, t test).
(F) Total action potential firing rate during 1 min recordings from MEAs of FACS-sorted 18a Hb9::GFP and 39b Hb9::GFP motor neurons recorded every 4 days
(repeated-measures ANOVA F-test p = 13 104 for difference between lines; post hoc t tests with Bonferroni correction for multiple testing indicated as *p < 0.05
and **p < 0.01). See also Figures S2 and S3.
(G) Total action potential firing rate during 1min of recording fromMEAs cultured for 14 days on the arrays (39b-Cor, n = 4; mean 775 ± 712 spikes/min; 39b, n = 4;
39b mean 6,278 ± 1,758 spikes/min; p = 0.01, t test).
Error bars represent SEM.of excitability, we assayed the number of action potentials fired
in response to a slow ramp depolarization. The number of action
potentials fired by ALS motor neurons was significantly greater
than control motor neurons (p < 0.05, Mann-Whitney U test; Fig-
ure 2B, upper panels, Figure 2C, upper panel). Resting mem-
brane potential, action potential threshold (rheobase), and input
resistance did not differ between ALS and control motor neurons
(Table S2), indicating that excitability differences were not due to
differences in electrophysiological health or baseline capacity for
action potential generation.
When we compared motor neurons derived from 39b-Cor and
39b cell lines in three separate additional parallel experiments,we again observed a marked difference in the number of action
potentials elicited during ramp depolarization (p < 0.05, Mann-
Whitney U test; Figure 2B, lower panels, Figure 2C, lower panel),
demonstrating that the A4V mutation was essential for the
phenotype. There was variability in the number of action poten-
tials in motor neurons from the same line tested across multiple
differentiations, but the increased number of action potentials
in ALS motor neurons relative to control motor neurons was
always preserved. This result underscores the importance of
performing repeated parallel differentiations in which equal
numbers of control and ALS motor neurons are analyzed from
each differentiation.Cell Reports 7, 1–11, April 10, 2014 ª2014 The Authors 3
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Figure 2. ALS Patient-Derived Motor Neurons Are Hyperexcitable
and Have Reduced Delayed-Rectifier Potassium Currents
Compared to Control-Derived Motor Neurons
(A) An iPSC-derived motor neuron identified by Hb9::RFP lentiviral trans-
duction (right) and during patch-clamp recording (left) after culture for 28 days.
Scale bar, 20 mm.
(B) Representative current clamp recordings during ramp depolarization from
control and ALS patient-derived motor neurons (upper four panels); sample
recordings from separate experiments comparing the isogenic correction of
the 39b SOD1A4V mutation (39b-Cor) and 39b (lower two panels).
(C) Upper panel: average number of action potentials elicited by ramp depo-
larization from control (11a, n = 12; 18a, n = 11; control mean 2.5 ± 0.4) and
ALS (39b, n = 13; RB9d, n = 12; ALS mean 4.2 ± 0.5) motor neurons obtained
from four separate differentiations (p < 0.05, Mann-Whitney U test). Lower
panel: separate experiments showing average number of action potentials
during ramp depolarization from 39b-Cor (n = 17; mean 4.1 ± 0.5) and 39b
(n = 19; mean 6.4 ± 0.9) motor neurons from three additional differentiations
(p < 0.05, Mann-Whitney U test).
(D) Sample voltage-clamp recordings from control and ALS-derived
Hb9::RFP-positive motor neurons cultured for 28 days.
(E) Average delayed-rectifier (DR) steady-state potassium current amplitude
relative to peak sodium current amplitude in control (11a, n = 12; 18a, n = 11;
control mean 0.88 ± 0.087) and ALS (39b, n = 13; RB9d, n = 12; ALS mean
0.44 ± 0.054) patient-derived motor neurons from four differentiations (p <
0.001, t test).
(F) Experiments from three separate differentiations showing average delayed-
rectifier steady-state potassium current amplitude relative to peak sodium
current amplitude in 39b-Cor (n = 18; mean 0.54 ± 0.061) and 39b (n = 19;
mean 0.32 ± 0.036; p < 0.005, t test).
(G) Direct measurement of delayed-rectifier voltage-gated potassium current
isolated by holding at 30 mV, stepping to a test-potential of +40 mV for 2 s
and normalizing steady state current amplitude to cell capacitance in 39b-Cor
(n = 19; mean 42.6 ± 4.3 pA/pF) and 39b (n = 18; mean 30.3 ± 3.1 pA/pF; p <
0.05, t test) derived motor neurons using cells from two additional separate
differentiations.
(H) Peak sodium current amplitude normalized to cell capacitance in 39b-Cor
(n = 16; mean 400.4 ± 44.7 pA/pF) and 39b (n = 15; mean 387.1 ± 50.5 pA/pF;
p = 0.8, t test) derived motor neurons.
Error bars represent SEM.
4 Cell Reports 7, 1–11, April 10, 2014 ª2014 The AuthorsIn addition to quantifying the electrical excitability of individual
neurons, patch-clamp recording enables quantitative investiga-
tion of specific currents that determine excitability. To identify
electrophysiological mechanisms responsible for the increased
firing of mutant motor neurons, we performed voltage-clamp ex-
periments using Hb9::RFP-positive motor neurons to examine
current components. As an index of excitatory and inhibitory
voltage-dependent ion channels, we quantified the ratio of out-
ward delayed-rectifier potassium current to inward transient so-
dium current. In four repeated differentiations of motor neurons
from control and SOD1A4V/+ iPSC lines, we observed that the
ratio of delayed-rectifier potassium to transient sodium current
was consistently smaller in SOD1A4V/+ motor neurons (p <
0.001, t test; Figures 2D and 2E). The difference was driven pri-
marily by the reduced delayed-rectifier potassium channel
component, as the difference in steady-state potassium current
amplitude normalized to individual cell capacitance between
ALS subjects and healthy controls was significant (control
137.0 ± 14.4 pA/pF, n = 23, versus ALS 94.4 ± 10.7 pA/pF, n =
25; p < 0.05, t test), whereas the peak sodium current normalized
to capacitance was not (control 190.3 ± 23.0 pA/pF, n = 21,
versus ALS 237 ± 21.2 pA/pF, n = 23; p = 0.2, t test). Because
voltage-gated potassium channels repolarize the membrane
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Figure 3. Retigabine Reduces Motor Neuron Excitability and In-
creases Survival
(A) Rheobase measurements in a 39b Hb9::RFP-positive ALS-derived motor
neuron in whole-cell patch clamp before (left) and after (right) the application of
10 mM retigabine (baseline rheobase 4.8 ± 1.5 pA versus post-retigabine
rheobase 8.4 ± 2.2 pA; n = 11; p < 0.05, Wilcoxon signed rank test).
(B) Representative current clamp recording showing effect of 10 mM retigabine
on membrane voltage and spontaneous firing (baseline Vm 60.4 ± 2.9 mV
versus post-retigabine Vm66.3 ± 3.6 mV, n = 11; p = 0.001, t test). In (A) and
(B), CNQX (15 mM), D-AP5 (20 mM), bicuculline (25 mM), and strychnine (2.5 mM)
were added to the external solution.
(C) Dose-response curve for retigabine on suppression of spontaneous action
potentials in MEA recording and Hill plot fit of mean data from 39b (n = 4) and
RB9d (n = 4) with EC50 1.5 ± 0.8 mM.
(D) Effect of vehicle (open circles) and 1mM retigabine (filled circles) treatment
from days 14–28 of culture on the survival of Islet-positive, Tuj1-positive motor
neurons measured at day 30 (total control n = 11; total ALS n = 9; F-test for
effect of retigabine on all cells p = 3.83 104; effect of retigabine in ALSmotor
neurons, red, 25.3% (SD 5.6; t test p = 6.4 3 105); effect of retigabine in
control motor neurons, black, 6.1% (SD 5.1, p = 0.23). Cell counts are from
individual wells for four separate differentiations.
See also Figure S4. Error bars represent SEM.potential back to negative values after an action potential, a
decrease in such currents likely contributes to increased action
potential firing in ALS motor neurons.
Correction of the disease-causing SOD1A4V/+ mutation also
increased the relative steady-state delayed-rectifier potassium
current amplitude, showing that this phenotypic difference spe-
cifically resulted from the A4V mutation (p < 0.005, t test; Fig-
ure 2F). We found amarked reduction in delayed-rectifier current
magnitude in 39b compared to 39b-Cor motor neurons (p < 0.05,
t test; Figure 2G) but no difference in sodium current peak ampli-
tudes (p = 0.8, t test; Figure 2H). Thus, correction of the deficit in
delayed-rectifier potassium current in 39b-Cor motor neurons
may enable repolarization of the membrane potential back to
normal hyperpolarized values and reduction of excitability to
levels in wild-type motor neurons.
Retigabine Blocks Motor Neuron Hyperexcitability and
Increases In Vitro Survival of SOD1A4V/+ ALS Motor
Neurons
Motor neurons express many types of voltage-activated potas-
sium channels and pharmacological dissection and quantifica-
tion into distinct components is challenging. Regardless of which
currents produce the hyperexcitability in diseased motor neu-
rons, Kv7 (KCNQ) channels are attractive targets for correcting
the hyperexcitability because of their activation at subthreshold
voltages and subsequent powerful control of excitability (Brown
and Passmore, 2009). Given this and the reduced delayed-recti-
fier potassium currents in ALS-derived motor neurons, we hy-
pothesized that retigabine, a specific activator of subthreshold
Kv7 currents and clinically approved anticonvulsant (Porter
et al., 2007), might block hyperexcitability in the SOD1A4V/+ mo-
tor neurons. In whole-cell patch clamp, retigabine significantly
increased theminimal current step necessary for action potential
generation (rheobase) by 3.6 ± 2.4 pA (p < 0.05, Wilcoxon signed
rank test; Figure 3A). Retigabine also stopped spontaneous firing
of Hb9::RFP-positive motor neurons and hyperpolarized the
resting membrane potential by 6.0 ± 2.2 mV (p = 0.001, t test;
Figure 3B). Because these experiments were performed with
blockers of glutamatergic, GABAergic, and glycinergic recep-
tors, retigabine must have a direct effect on motor neuron excit-
ability. We used MEA recordings to determine a dose-response
for inhibition of spontaneous firing by retigabine of SOD1A4V/+
ALS-derived neurons. Retigabine suppressed ALS neuron spon-
taneous firing with an EC50 of 1.5 mM (Figure 3C), a concentration
consistent with its pharmacological activity as an antiepileptic
agent and similar to its EC50 for Kv7 channels (Wickenden
et al., 2000). In line with this finding, analysis of RNA sequencing
(RNA-seq) data from FACS-sorted motor neurons (Kiskinis et al.,
2014) confirm expression of Kv7 channels (Table S3).
To evaluate the possibility that hyperexcitability is an upstream
modulator of motor neuron degeneration in ALS, we tested if re-
tigabine affects the survival of control and SOD1A4V/+ motor neu-
rons over 30 days in culture. As observed by Kiskinis et al. under
basal conditions, the loss of SOD1A4V/+ motor neurons was
greater than SOD1+/+ control motor neurons (Kiskinis et al.,
2014). Two weeks of treatment with retigabine (1 mM) increased
the number of ALS motor neurons in vitro by 25% (p < 104,
t test; Figure 3D) to levels found in controls.Cell Reports 7, 1–11, April 10, 2014 ª2014 The Authors 5
AB C
Figure 4. Hyperexcitability of C9orf72 Repeat Expansion-Derived
Motor Neurons
(A) Representative recordings from four/64 MEA electrodes recorded from
control (11a, 18a) and C9orf72 expansion ALS-derived neurons (19f, RB8b)
cultured for 14 days.
(B) Total action potential firing rate during 1 min of recording from MEAs (11a,
n = 1; 18a, n = 3; control mean 4,752 ± 2,786 spikes/min; 19f, n = 3; RB8b,
n = 3; ALS mean 20,022 ± 3,775 spikes/min; p < 0.05, t test).
(C) Average of mean firing rate for control and C9orf72-derived neurons (11a,
n = 82; 18a, n = 203; control mean 1.11 ± 0.06 Hz; 19f, n = 407; RB9d, n = 929;
ALS mean 1.50 ± 0.04; p < 105, t test).
Error bars represent SEM.To investigate how retigabine increases the survival of
SOD1A4V/+ ALSmotor neurons, we determined whether it affects
pathways suspected to contribute to motor neuron death in ALS
(Robberecht and Philips, 2013). We chose to look at endo-
plasmic reticulum (ER) stress because of the demonstration
that ER stress pathways are activated in SOD1A4V/+ ALS
compared to SOD1+/+ motor neurons (Kiskinis et al., 2014). After
2 weeks of treatment with retigabine (1 mM), XBP1 splicing was
markedly decreased in retigabine compared to vehicle-treated
39b SOD1A4V/+ ALS motor neurons (Figures S4A and S4B). In
addition to reduced XBP1 splicing, we observed a decrease in
PUMA and increase in EIF2B3 transcript levels, consistent with6 Cell Reports 7, 1–11, April 10, 2014 ª2014 The Authorsdownregulation of ER stress in response to retigabine treatment
(Figure S4C).
Motor Neuron Hyperexcitability Is Present in Distinct
ALS Forms and Is Blocked by Kv7 Activators
In order to investigate whether motor neuron hyperexcitability
generalized to additional ALS variants, we performed MEA re-
cordings of motor neurons derived from iPSC lines made from
two unrelated familial ALS patients with C9orf72 hexanucleotide
repeat expansion (19f and RB8b) (Kiskinis et al., 2014), which is
responsible for 40%–50% of familial ALS and approximately
10% of sporadic cases (Robberecht and Philips, 2013). Motor
neurons derived from these patients also showed significant hy-
perexcitability compared to controls in both total firing rate (p <
0.05, t test; Figures 4A and 4B) and averagemean neuronal firing
rate (p < 105, t test; Figure 4C).
We reasoned that comparing neuronal firing properties of a
large group of ALS patient and control-derived motor neurons
would help evaluate the robustness of the motor neuron
hyperexcitability and, together with the A4V gene correction ex-
periments, eliminate artifacts due to cell line variation. SOD1-
derived motor neurons (four lines from four unrelated subjects
harboring three different mutations), C9orf72-derived motor
neurons (two lines from two unrelated subjects), fused-in-
sarcoma (FUS)-derived motor neurons (two lines from two un-
related subjects harboring two different mutations) were all
hyperexcitable relative to motor neurons derived from six
iPSC lines made from five individual healthy controls (ANOVA,
p < 107; Tukey’s post hoc tests for control versus SOD1 p <
0.01, control versus C9orf72 p < 0.01, control versus FUS
p < 0.05; Figure 5A). Furthermore, spontaneous action potential
firing in the ALS variant-derived motor neurons was uniformly
blocked by retigabine (Figure 5B). Consistent with an on-target
effect of retigabine, we found that a chemically distinct but less
potent Kv7 current enhancer, flupirtine (Brown and Passmore,
2009), also blocked spontaneous motor neuron firing (Fig-
ure 5C). These results demonstrate the broad relevance of
motor neuron hyperexcitability for familial ALS and its sensi-
tivity to Kv7 agonists across iPSC lines, patients and genotypic
etiologies.
DISCUSSION
Neurons derived from patient iPSCs can be used to investigate
physiological changes in specific neural subtypes relevant to
neurodegeneration and reveal important disease mechanisms
and candidate therapeutics. We found consistent hyperexcit-
ability in motor neurons from a broad group of familial ALS pa-
tients, whose disease-causing mutations collectively span the
majority of familial ALS cases. Differential excitability of partic-
ular motor neurons has been proposed to explain the selective
vulnerability of specific motor neuron pools in ALS, and our
data provide a possible mechanistic basis for this hypothesis
(Bae et al., 2009; Saxena and Caroni, 2011).
Motor neuron hyperexcitability may contribute, therefore, to
motor neuron death, although connections between hyperexcit-
ability and motor neuron death in other ALS variants will now
require investigation. Our results are consistent with multiple
AB C
Figure 5. Motor Neuron Hyperexcitability
and Block by Retigabine Are Broad Proper-
ties of ALS Variants
(A) Multielectrode array recordings of motor neu-
rons derived from control (11a, n = 8; 15b, n = 2;
17a, n = 5; 18a, n = 7; 18b, n = 10; 20b, n = 6),
SOD1 (25b, D90A, n = 3; 27d, G85S, n = 7; 39b,
A4V, n = 3; RB9d, A4V, n = 7), C9orf72 expansion
(19f, n = 2; RB8B, n = 13) and FUS (MGH5b,
frameshift mutation at residue 511, n = 10; RB21,
H517Q, n = 4) subjects cultured for 14 days.
ANOVA, p < 107; Tukey’s post hoc tests for
control versus SOD1 p < 0.01, control versus
C9orf72 p < 0.01, control versus FUS p < 0.05. For
subject 18, motor neurons from two different iPSC
lines were recorded. Error bars are 95% confi-
dence interval. See also Figure S5.
(B) Dose-response curve for retigabine on sup-
pression of spontaneous action potentials in MEA
recording and Hill plot fit of mean data from SOD1
(n = 10; EC50 1.9 ± 0.5 mM), C9orf72 (n = 9; EC50
2.6 ± 0.8 mM) and FUS (n = 4; EC50 1.9 ± 1.1 mM).
(C) Dose-response curve for flupirtine on sup-
pression of spontaneous action potentials in MEA
recording and Hill plot fit of mean data from SOD1
(n = 5; EC50 9.8 mM), C9orf72 (n = 4; EC50 19.4 mM)
and FUS (n = 2; EC50 15 mM).
Error bars for (B) and (C) represent SEM.studies of excitotoxicity (Cleveland and Rothstein, 2001; Fritz
et al., 2013) but, potentially, not with two recent studies. One
postulated that increased excitability in the SOD1G93A mouse
model may be a compensatory mechanism (Saxena et al.,
2013). However, systemically administered glutamatergic and
cholinergic modulators may affect multiple neuronal types, mak-
ing it difficult to assess how the findings relate to motor neuron
excitability, which was not measured. A second study found
decreased numbers of elicited spikes in iPSC-derived motor
neurons from ALS patients with C9orf72 repeat expansion
compared to controls (Sareen et al., 2013). The differences in
spike count here may reflect the longer differentiation time (66–
79 days), differences in surviving neuronal populations or alter-
ations in resting membrane potential in C9orf72 compared to
control neurons. For example, the more depolarized resting po-
tential in C9orf72 expansion-derived neurons could result in
greater sodium channel inactivation and reduced capacity for
generation of multiple action potentials; indeed, depolarization-
induced action potential blockade may be a late phase of pro-
gressive hyperexcitability. Mouse SOD1G93A motor neurons
show hyperexcitability even at an embryonic age (Kuo et al.,
2004; Pieri et al., 2003; van Zundert et al., 2008), and neurophys-
iological studies reveal increased excitability in C9orf72 repeat
expansion subjects (Williams et al., 2013) in addition to other fa-
milial and sporadic ALS cases (Blair et al., 2010; Mills and Nithi,
1997; Vucic and Kiernan, 2006, 2010).Cell Reports 7,Previously, attention has focused on
persistent sodium currents as a mecha-
nism of motor neuron hyperexcitability
(Kuo et al., 2005; Vucic and Kiernan,2010), and riluzole, the only approved drug for ALS, blocks this
current (Urbani andBelluzzi, 2000). Our findings suggest an addi-
tional important role of voltage-activated potassium channels.
Channel compartmentalization may differ between in vivo and
cultured-neuron systems; however, a recent immunohistochem-
ical study of human spinal cords found decreased protein levels
of a delayed-rectifier potassium channel selectively in the ventral
roots of sporadic ALS but not control subjects (Shibuya et al.,
2011). Mutations in voltage-gated potassium channels cause
other neurodegenerative diseases (Waters et al., 2006), and
oxidation of potassium channels (with consequent modulation
of voltage-dependence and kinetics of channel gating) has
been suggested as a broad mechanism of aging and neuro-
degeneration (Sesti et al., 2010). DPP6, which is involved in
trafficking Kv4 voltage-gated potassium channels in CA1 hippo-
campal neurons, is linked to ALS (Sun et al., 2011; van Es et al.,
2008). Hypermethylation anddownregulation of potassiumchan-
nel genes were observed in epigenetic analyses of postmortem
ALS patient spinal cords (Figueroa-Romero et al., 2012).
Both enhanced persistent sodium and reduced potassium
currents could converge to produce hyperexcitability, and both
may offer complementary pharmacological targets to control it.
Although our study evaluated hyperexcitability as an innate or
autonomous property of motor neurons, differences in excit-
ability may also reflect interactions between motor neurons
and glia or Schwann cells (Fritz et al., 2013). Hyperexcitability1–11, April 10, 2014 ª2014 The Authors 7
has also been observed inmotor neurons from amousemodel of
spinal muscular atrophy (Mentis et al., 2011), and there is evi-
dence for both cell autonomous (Gogliotti et al., 2012) and
nonautonomous (Imlach et al., 2012) modulation of excitability.
Interestingly, spinal muscular atrophy has also been linked to
DPP6, raising the possibility of potassium channel contributions
(van Es et al., 2009).
The pathways connecting disease-causing mutations and
decreased potassium channel function, and between hyperex-
citability and motor neuron death remain to be clarified. Calcium
overload through voltage-gated calcium channels (Chan et al.,
2007) and activation of ER stress (Saxena and Caroni, 2011)
are possibilities. The finding that decreasing motor neuron activ-
ity reduces ER stress suggests that hyperexcitability may be
upstream of the unfolded protein response, explaining at least
partially how hyperexcitability may contribute to motor neuron
death in ALS. Because ER stress modifiers increase motor
neuron activity, a vicious cycle may result in ALS from reciprocal
positive feedback between hyperactivity and ER stress (Kiskinis
et al., 2014).
Despite the asymptomatic early decades typical of ALS
patients, we observed a disease-specific phenotype in iPSC-
derived neurons cultured for only weeks. That this property man-
ifests so quickly in culture may reflect the absence of supporting
cells and the inhibitory circuitry normally present in vivo. Identifi-
cation of a screenable electrophysiological phenotype that
contributes to motor neuron death and manifests quickly could
facilitate investigation of ALS pathophysiology and identification
or validation of therapeutics for individual patients. Furthermore,
the phenotype may offer a personalized medicine approach to
treatment, using response of stem cell-derived neurons as a
guide for individual patient treatment selection; this strategy
will require motor neurons derived from large cohorts of patients
for validation. Studies of motor neuron excitability can now be
expanded to determine whether all forms of ALS converge
onto a single mechanistic pathway. More generally, our study
illustrates the potential for using iPSCs differentiated into spe-
cific disease-relevant cell types to identify disease phenotypes,
novel biomarkers, and potential treatments.EXPERIMENTAL PROCEDURES
iPSC Lines, Culture, and Motor Neuron Differentiation
iPSC generation from patient fibroblasts obtained under institutional review
board approval, characterization, and motor neuron differentiation were per-
formed as described in Kiskinis et al. (2014) and Figure S5, with iPSC line
scoring as done previously (Bock et al., 2011). For transfection of 18a and
39b lines with a Hb9::GFP reporter (Figure S3), a 1 kb Hb9 promoter fragment
(gift from Hynek Wichterle) controlling the expression of myristoylated GFP
was inserted into a donor plasmid specific for the AAVS1 locus (Sigma). Sub-
sequently, 2.5 million iPS cells were accutased and electroporated using the
Neon transfection system (100 ml tip; 1,600 V voltage, 20 ms width, 1 pulse;
Life Technologies) with 2 mg of AAVS1 ZFN plasmid and 6 mg of modified
AAVS1 donor plasmid. After nucleofection, cells were plated on matrigel
with mTeSR1 in the presence of ROCK inhibitor. After 48 hr, puromycin selec-
tion was applied, and surviving clonal colonies were individually passaged and
genomic DNA was extracted. PCRwas used to confirm proper targeting of the
cassette. Primer sequences are available upon request. Faithful expression of
the reporter was verified using expression of the motor neuron marker Isl1
(Figure S3C).8 Cell Reports 7, 1–11, April 10, 2014 ª2014 The AuthorsiPSCs were maintained on culture dishes as described previously (Boulting
et al., 2011) with modifications (Kiskinis et al., 2014) in a 24 day protocol based
on initial neuralization with SB431542 (10 mM, Sigma-Aldrich) and Dorsomor-
phin (1 mM, Stemgent), and motor neuron patterning with RA (Sigma) and a
small smoothened Agonist 1.3 (Calbiochem). For Figure 1F, FACS-purified
neurons were grown on a confluent monolayer of primary cortical mouse
glia prepared from P0–P2 mouse pups (as described in Boulting et al.,
2011), which may increase firing rates compared to experiments without glia
(Boehler et al., 2007).
MEA Recording
After 24 days of differentiation, equal numbers of control and ALS neurons
were plated on poly-D-lysine/laminin coated p515A probes (Alpha Med Scien-
tific) or M768-GLx 12-well plates (Axion BioSystems) at typical densities of
40,000–80,000/ probe or well. All probes were visualized immediately before
each recording session to confirm a full monolayer of cells. Initial experiments
(11a, 18a, 39b, and RB9d comparison) were performed as close as possible to
the time of patch recordings (4 weeks). However, because we wished to eval-
uate firing at a time point prior to significant motor neuron death (Kiskinis et al.,
2014), we performed subsequent experiments (39b-Cor and 39b comparison
and all later experiments) at day 14 after dissociation (Table S1).
Recordings from 64 extracellular electrodes were made using a Med64
(Alpha Med Scientific) or Maestro (Axion BioSystems) MEA recording amplifier
with a head stage that maintained a temperature of 37C. For Med64 record-
ings, data were sampled at 20 kHz, digitized, and analyzed by spike clustering
and spike extraction algorithms using Mobius software (Alpha Med Scientific)
with a 2 kHz 9-pole Bessel low pass filter, 10 mV action threshold detection
limit, and 30% cluster similarity radius. These standard settings were main-
tained for all analyses. We confirmed that we obtained similar results across
a wide range of action potential threshold and cluster similarity radius settings.
Correlation analysis to detect and correct for clusters detected by multiple
electrodes was performed using custom MATLAB software. Total action po-
tential firing rates and mean neuronal firing frequencies were then determined
and plotted. In order to record in larger replicates, we used the Axion Maestro
MEA device, in a 12-well format with 64 extracellular electrodes in each
well. For Maestro recordings, data were sampled at 12.5 kHz, digitized, and
analyzed using Axion Integrated Studio software (Axion BioSystems) with a
200 Hz high pass and 2.5 kHz low pass filter and an adaptive spike detection
threshold set at 5.5 times the SD for each electrode with 1 s binning. These
standard settings were maintained for all Axion MEA recording and analysis.
For retigabine dose-response curves, action potential numbers during 1min
of recording in each concentration of retigabine were normalized to the initial
action potential number during 1 min of recording in standard extracellular
saline solution. The EC50 value was determined by fitting the mean normalized
data values to the Hill equation, y = 1/((EC50/x)
nH+1) where nH is the Hill
coefficient.
Patch Electrophysiology
Whole-cell patch recordings were performed on iPS-derived motor neurons
identified by transduction with an Hb9::RFP lentivirus. Lentiviral transduction
was typically performed 7–10 days before recording. Two large comparisons
were performed, one consisting of 11a, 18a, 39b, and RB9d, and the second
consisting of 39b-Cor and 39b. Each comparison was made from pooled data
from multiple separate experiments, each consisting of synchronous and par-
allel iPSC culture and differentiation, embryoid body dissociation, plating, and
maturation of control- and ALS-derived neurons. Equal numbers of control and
ALS motor neurons were recorded from each experiment. Comparison of the
original four lines (11a, 18a, 39b, and RB9d) was made using four separate
parallel differentiation experiments, whereas comparison of the isogenic
correction comparison (39b-Cor and 39b) was performed using three separate
parallel differentiation experiments.
For each experiment, neurons from control and ALS lines were dissociated
after 24 days of differentiation and plated onto poly-d-lysine/laminin coated
glass coverslips (20,000–40,000/coverslip) and allowed to mature for 4 weeks
from start of differentiation. We chose 4 weeks as the best time point because
this yielded the most homogeneous population of mature-appearing
Hb9::RFP-positive motor neurons (at the requisite low cell density for patch
clamp) with the most mature electrophysiological properties. Whole-cell cur-
rent-clamp and voltage-clamp recordings were performed using a Multiclamp
700B (Molecular Devices) at room temperature (21C–23C). Data were
sampled at 20 kHz and digitized with a Digidata 1440A A/D interface and re-
corded using pCLAMP 10 software (Molecular Devices). Data were low-pass
filtered at 2 kHz. Patch pipettes were pulled from borosilicate glass capillaries
on a Sutter Instruments P-97 puller and had resistances of 2–4MU. The pipette
capacitance was reduced by wrapping the shank with Parafilm and compen-
sated for using the amplifier circuitry. Series resistance was typically 5–10MU,
always less than 15 MU, and compensated by at least 80%. Neurons were
excluded from analysis if holding current at 80 mV exceeded 100 pA, input
resistance was less than 250 or greater than 2000 MU, or spikes elicited
from 65 mV had peaks below 0 mV. Resting membrane potential was deter-
mined by averaging for 20 s of recording, and afterward a small holding current
(typically with amplitude less than 5 pA) was used to clamp the resting mem-
brane potential as close as possible to 65 mV. Rheobase was measured by
applying 1 s steps in increments of 2.5 pA until an action potential was gener-
ated. Current ramps were elicited from an initial hyperpolarizing current of
10 pA for 1 s followed by a 210 pA/s depolarizing ramp of duration 1 s. Spikes
on the ramps were counted if the peak voltage exceeded 10 mV. Action po-
tential properties (Table S2) were determined using custom-written analysis
software in Igor Pro (Wavemetrics) with DataAccess (Bruxton) for importing
the files. For voltage-clamp recordings, voltages were elicited by 100 ms de-
polarizing steps from a holding potential of 80 mV to test potentials ranging
from 80 mV to 50 mV in 10 mV increments. For the latter gene correction ex-
periments, the step length was increased to 200 ms to assay delayed-rectifier
currents after more complete decay of transient potassium currents. For reti-
gabine patch applications, resting membrane potential was recorded immedi-
ately before and 10 s after the application of 10 mM retigabine (in each case,
membrane potential was an average of values sampled for 20 s). For all patch
experiments, series resistance was monitored by brief 5 pA hyperpolarizing
steps during current clamp recordings and by 5 mV hyperpolarizing steps dur-
ing voltage-clamp recordings. Electrode drift was measured at the end of each
recording and was typically 1–2 mV. The extracellular solution was sodium-
based and contained 135 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2,
10 mM glucose, 10 mM HEPES 10 (pH 7.4). The intracellular solution was po-
tassium based and contained 150mMKCl, 2mMMgCl2, 10mMHEPES, 4mM
MgATP, 0.3 mM NaGTP, 10 mM Na2PhosCr, 1 mM EGTA (pH 7.4). For isola-
tion of delayed-rectifier potassium channels (Figure 2G), 300 nM TTX and
100 mM CdCl2 were used to block voltage-gated sodium channels and
voltage- and calcium-activated potassium channels, respectively. For isola-
tion of voltage-gated sodium currents (Figure 2H), internal KCl was replaced
by CsCl to block potassium currents and 100 mM CdCl2 was used to block
calcium currents.
Cell Survival and ER Stress Assays
Dissociated neurons (20,000) were plated on poly-D-lysine/laminin coated
8-well chamber slides (BD Biosciences) containing a confluent monolayer of
primary cortical mouse glia (Boulting et al., 2011). For survival analysis, slides
were fixedat 3 and30days, andcultureswere stained for counting. Thenumber
of ISL-positive, TUJ1-positive motor neurons (counter blinded to cell line iden-
tity) was normalized to the number on day 3 for each line. Retigabine (1 mM) or
vehicle control was added from day 15 onward. Eleven total experiments (con-
trol motor neurons) and nine total experiments (ALS motor neurons) were per-
formed from the same four separate differentiations. ER stress experiments
were performed as described in Kiskinis et al. (2014). In brief, in two separate
independent biological replicates, 300 ng of RNA was used to generate
cDNA, of which 2 ml and AmpliTaq Gold Polymerase (Applied Biosystems)
were used for PCR amplification. The amounts of spliced and unspliced bands
werequantifiedusing ImageJ.QuantitativeRT-PCRwasperformed in triplicate
using the iSCRIPT kit (Bio-Rad) for cDNA synthesis and SYBR green (Bio-Rad)
labeling followed by amplification using the iCycler system (Bio-Rad).
Drugs
Drugs included retigabine (Santa Cruz Biotechnology), bicuculline, strychnine,
D-AP5, CNQX, flupirtine, TTX (all from Tocris Bioscience). CsCl and CdCl2
were from Sigma.Statistical Analysis
p < 0.05 was considered statistically significant. Comparisons were made be-
tween control and ALS populations using t tests (two-tailed, unpaired)/ANOVA
for continuous data and rank tests for nonparametric data (discrete measure-
ments of number of spikes on ramps and rheobase). For analysis of MEA firing
over time (Figure 1F), we used amixed repeated-measures ANOVAmodel with
fixed effects of cell line and time and random effects of individual replicate. For
effect of retigabine on specific cells (Figures 3A and 3B), paired tests were
used. For effect of retigabine on survival (Figure 3D), we fitted a linear regres-
sion model with effects of retigabine treatment, cell line, and their interaction.
F-tests for difference between ALS and control lines gave p = 0.0011, for effect
of retigabine p = 3.83 104, and for effect modification p = 0.015. For ALS sub-
jects, the effect of retigabine was an increase in cell count of 25.3% (SD 5.6,
p = 6.4 3 105). The effect estimate for 39b was 16.9% (SD 12.9, p = 0.03)
and for RB9d 39.9% (SD 11.3, p = 0.001). For control subjects, the effect of
retigabine was an increase in cell count of 6.1% (SD 5.1, p = 0.23). For multiple
genotype comparisons (Figure 5A), one-way ANOVA after log transformation
to normalize variance and post hoc Tukey tests were used to analyze multiple
ALS variants. Error bars represent SEM unless indicated.
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